#United States #San Diego #Halozyme #Financial Growth #ENHANZE

Halozyme's Stellar Performance in Q3 2026

Halozyme Therapeutics, Inc. (Nasdaq HALO), a biopharmaceutical firm known for its innovative solutions in drug delivery technology, unveiled its financial results for the third quarter ending September 30, 2026. The report highlighted a significant year-over-year revenue growth of 39%, reaching a total revenue of $493 million, alongside a notable 44% rise in royalty revenue that accounted for $341 million. This robust performance has prompted the company to adjust its full-year 2026 financial guidance upwards, showcasing its undeniable strength in the industry.

Corporate Milestones

Dr. Helen Torley, President and CEO of Halozyme, expressed her satisfaction with the company's progress, stating that the quarter had seen multiple milestones reached that broaden the company's future opportunities and diversify revenue streams. Recently, Halozyme expanded its collaboration agreements with partners like argenx and Incyte to target additional drugs for evaluation using their proprietary ENHANZE® technology. In October 2026, Halozyme struck a deal with Johnson & Johnson, adding yet another target to their collaboration.

Moreover, three ENHANZE® programs made strides into Phase 1 clinical development, raising the total count of ongoing product developments to twelve. These advancements are testament to Halozyme's strategic planning and growth potential in a competitive market.

Legal Victory

Adding to their recent achievements, a recent ruling from a Dutch patent court found that Merck infringed on one of Halozyme's patents, granting an injunction against the launch of Keytruda Qlex in several European markets. Such legal victories not only protect Halozyme’s intellectual property but also reinforce the company’s commitment to safeguarding the value of its innovations.

Financial Performance Breakdown

For Q3 2026, Halozyme's operating income surged to $295 million, up from $217.9 million the previous year. The net income also experienced a significant increase, reaching $247 million compared to $175 million in Q3 2025. The adjusted EBITDA for the quarter stood at $336 million, indicating a strong growth trajectory with solid contributions from ongoing sales and collaborations. The company's diluted earnings per share (EPS) also rose impressively, reaching $2.39, compared to $1.72 in the same period the previous year.

The financial outlook for 2026 has been adjusted based on this quarter's performance, revealing expectations of a substantial total revenue between $1.860 billion and $1.925 billion, showcasing a year-on-year growth of 33% to 38%. Royalty revenue is projected to contribute significantly, with estimates between $1.235 billion and $1.255 billion—an anticipated growth of 42% to 45%. Adjusted EBITDA is expected to rise notably, reaching between $1.240 billion and $1.290 billion.

Looking Forward

As Halozyme continues to build on its successes, it remains focused on delivering high-value innovations and expanding its partnerships. The company also reinforced its financial strategy through the successful completion of $1.5 billion in convertible notes, which provides additional flexibility for capital deployment and strategic investments in growth opportunities. Furthermore, shares worth $400 million were repurchased in 2026, illustrating the confidence the management holds in the company’s future.

In summary, Halozyme's Q3 2026 results reveal a commendable performance backed by solid revenue growth, increased collaborations, and a strong financial position, laying a strong foundation for the years to come.